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Background: Androgen Deprivation Therapy (ADT) is a commonly used treatment for 
prostate cancer with controversy currently surrounding its association with long-term 
cardiovascular disease risk. Therefore, the aim of the current investigation was to non-invasively 
measure left ventricular mechanics at rest and during submaximal exercise in human prostate 
cancer survivors with and without a history of ADT.  
Methods: Eighteen prostate cancer survivors, 9 with a history of ADT and 9 matched 
(1:1) non-ADT controls, completed the protocol. Standard and tissue Doppler echocardiography 
were used to evaluate left ventricular systolic and diastolic function at rest and during 
submaximal cycling exercise.   
Results: At rest, there were no differences between groups. Ejection fraction was not 
different between groups at rest or during exercise (rest p=0.7; exercise p=0.8). During exercise, 
systolic left ventricular longitudinal strain and strain rate failed to increase in the ADT group 
(p=0.4; p=0.07), but significantly increased in the non-ADT group (p=0.03; p=0.02). During 
exercise, systolic strain was significantly different between groups (p=0.02). Diastolic 
longitudinal strain increased with exercise in both groups (p=0.003; p=0.003). In the ADT group 
during exercise, mitral valve deceleration time was not significantly different from rest (p=0.8) 
and was slower compared to non-ADT (p=0.03).  
Conclusion: In prostate cancer survivors with a history of ADT, there are significant 
abnormalities of left ventricular systolic function that become apparent with exercise. These 
findings may hold significant value beyond the standard resting characterization of ventricular 
function, in particular as part of a risk-stratification strategy. 
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Chapter 1 - Introduction 
Prostate cancer is the most common non-skin cancer among American men, with 
approximately 1 in 9 men diagnosed with prostate cancer during their lifetime (28), resulting in 
an estimated 3.5 million new cases over the next 20 years. Currently, the standard treatment 
recommendations for prostate cancer consists of some combination of surgery, radiation therapy, 
and/or androgen-deprivation therapy (ADT). ADT targets testosterone, the main androgen that 
stimulates prostate cancer cell growth, and can inhibit post-surgical growth or diminish the size 
of the tumor in some patients (17). As such, ADT is commonly prescribed for prostate cancer 
with nearly 40-50% of patients receiving ADT within the first six months post-diagnosis (23) 
with treatment lasting 2 to 3 years (3).  
 
 Despite the effectiveness of ADT, possible side effects related to ADT and long-term 
cardiovascular disease (CVD) morbidity and mortality may occur (16). Evidence from several 
studies suggest that ADT-induced hypotestosteronemia increases cardiac morbidity by 20% in 
the first 12 months of treatment (12, 13, 21). Additionally, ADT has been associated with 
changes in CVD risk factors, including: visceral adiposity, insulin resistance, decreased high-
density lipoprotein, increased low-density lipoprotein, and increased triglycerides (21). Recently, 
Keating et al. (13) found that prior ADT was associated with an 11% increased risk of 
myocardial infarction (MI), 16% increased coronary heart disease risk, and a 16% increased risk 
of sudden cardiac death. Conversely, Nguyen et al. (18) found no difference in long- or short-
term CVD death in prostate cancer patients with a history of ADT compared to non-ADT 
controls. In their study the ADT treated men also had lower rates of Prostate Cancer-Specific 
Mortality, and a lower all-cause mortality, as compared to other treatment groups. These findings 
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were further supported by Efstathiou et al. (4) who observed a lower CVD mortality (8.4% vs 
11.4%) in men receiving a luteinizing hormone-releasing hormone (LHRH) agonist, such as 
Leuprolide. Due to the significant controversy (16) and potential clinical concerns over this 
issue, additional work is needed to determine the interaction between ADT and cardiovascular 
health.  
 
Echocardiographic assessment of myocardial deformation, specifically left ventricular 
(LV) strain and strain rate, is an emerging non-invasive method used for detecting subclinical 
ventricular dysfunction and has been shown to provide significant prognostic value in many 
patient populations (6, 27). Thus, evaluation of LV strain and strain rate provides a non-invasive 
method to both evaluate and monitor changes in CVD risk in prostate cancer survivors treated 
with ADT, which to our knowledge has not been previously investigated. Therefore, the primary 
aim of the current study was to investigate non-invasive measurements of LV function in 
prostate cancer survivors with and without a history of ADT. It was hypothesized that prostate 
cancer patients with a treatment history including ADT would have decreased LV systolic and 
diastolic functional parameters (e.g., velocities, mitral valve parameters, strain, and strain rate) 
compared to non-ADT controls at rest. Since exercise as a stressor reveals LV dysfunction that 
can be obscure at rest (15), we further hypothesized that during exercise, these functional 
parameters would remain unchanged in response to exercise in the ADT treated patients resulting 
in significant differences between ADT and non-ADT patients.  
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Chapter 2 - Methods 
Study Design and Participants 
 
The present study utilized a case-control cross-sectional study design. Prostate cancer 
survivors were assigned to either an ADT or non-ADT group, based on their cancer treatment 
history. A total of 9 prostate cancer survivors with a history of ADT were screened for eligibility 
and enrolled into the study (ADT group). These ADT treated patients were propensity score 
matched (1:1) with a control group consisting of prostate cancer survivors with no history of 
ADT (non-ADT group) based on age, body mass index (BMI) and submaximal exercise 
capacity. Patients were excluded from participation if they had any of the following: 
uncontrolled hypertension, unstable angina, diabetes, known atherosclerotic CVD, uncontrolled 
cholesterol, current smoker, or history of myocardial infarction. Some participants were taking 
antihypertension medications (ADT, n=8; non-ADT n=3) and statins (ADT, n=3; non-ADT 
n=6), but at similar proportions between groups. To increase ecological validity and minimize 
acute changes in systemic cardiovascular function associated with drug withdrawal, these 
medications were not withheld before testing. All procedures were approved by the Kansas State 
University Institutional Review Board for research involving human subjects, and all standards 




All testing was conducted following a >4 hr fast in a temperature-controlled clinical 
environment (~20°C–22°C). All patients underwent a preliminary introductory session to obtain 
4 
written informed consent, physician approval, and completion of a general health history 
questionnaire. Following physician approval, LV mechanics and sub-maximal cardiorespiratory 
exercise performance were assessed on a subsequent visit. Testing order was not randomized 
with assessments of LV function always preceding the graded cardiorespiratory exercise test.  
 
2-dimensional and tissue Doppler echocardiography. Each participant was placed supine 
on an echocardiographic table that utilizes a unique tilt function to place the patient into the 45° 
left-lateral decubitus position, while supporting the torso, hips, and legs. Patients were 
instrumented for continuous beat-by-beat systolic, diastolic, and mean blood pressure (SBP, 
DBP, and MAP, respectively) measurements via calibrated continuous finger plesmythography 
(Finometer Pro; Finapress Medical Systems, Amsterdam, The Netherlands). A three-lead 
echocardiogram (ECG) was used to continuously measure heart rate (HR). Following a 5 min 
acclimation period, transthoracic echocardiography was performed at rest and during exercise by 
an experienced sonographer, according to the standards of the American Society of 
Echocardiography using a commercially available system (Vivid S6 BT12; GE Healthcare) with 
a 1.5- to 4.3-mHz phased array transducer. Exercise consisted of a 20 W min-1 ramped cycle on a 
supine bicycle ergometer (Lode Angio, Groningen, Netherlands) used to increase heart rate to 
100 beats per minute, which was then maintained throughout the test. Breath-by-breath 
pulmonary ventilation and gas exchange data were continuously measured (Ultima CPX, 
Medical Graphics Corp.,MN, USA) and averaged across the resting baseline and during steady-
state exercise.  
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For a given participant, LV systolic and diastolic function were derived via apical 4-
chamber two-dimensional images. For all LV measurements the average of three consecutive 
cardiac cycles were used. LV volumes were quantified at end-systole (ESV) and end-diastole 
(EDV) via the perpendicular axis from the apex to the distal boundary of the mitral valve (MV) 
leaflets. LV ejection fraction (LVEF) was calculated as LVEF = [(EDV-ESV)/EDV] × 100. 
Stroke volume (SV) and cardiac output (Q) were calculated as SV = ESV – EDV and Q = SV x 
HR, respectively. MV early filling (E) and atrial filling (A) peak velocities, E/A ratio, and E-
wave deceleration time (MVdecT) were measured via pulse-wave Doppler from the transmitral 
flow with the sample volume placed between the MV leaflets. The peak systolic (Sm), early 
diastolic (Em), and late diastolic (Am) mitral annular velocities of the septal wall were measured 
via color tissue Doppler in the apical 4-chamber view at a constant rate of 100 frames/s using a 
narrow sector and high frame rate and by placing the sample volume in the basal segment of the 
interventricular septum.  
 
Peak LV tissue Doppler longitudinal strain and strain rate were obtained from derived 
from 2-dimensional apical images and analyzed using the software incorporated in the Vivid S6 
system as previously described (24). In each patient, the sonographer ensured longitudinal 
movement was in direct line with the ultrasound beam. Sample volumes were placed along the 
basal, mid-, and apical LV segments of the septal wall and averaged to give a mean value for the 
entire septal wall. From this, longitudinal myocardial function was evaluated using peak systolic 
strain, peak systolic strain rate, and early filling strain rate averaged across three consecutive 
cardiac cycles. Briefly, LV strain provides a dimensionless measure of ventricular myocardial 
fiber deformation during the cardiac cycle relative to its initial length (i.e., reported as 
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percentage). Strain rate (the first derivative of strain) is the rate of myocardial deformation 
during systolic and early filling periods of the cardiac cycle (11). 
 
Graded Cardiopulmonary Exercise Test. Upon completion of the echocardiographic 
examination, each patient was given 15-20 min recovery period followed by a symptom-limited, 
ramped, incremental exercise protocol on a semi-recumbent cycle ergometer to determine their 
submaximal aerobic exercise capacity (Lode, Corival). Following a 5-min resting baseline, 
subjects pedaled at 50–60 rpm with progressive increases in power output at a rate of 20 W min-1 
until the patient reached 85% of their age-predicted heart rate. Breath-by-breath pulmonary 
ventilation and gas exchange data were continuously measured (Ultima CPX, Medical Graphics 
Corp., MN, USA) and averaged into 15 second mean values. The pulmonary oxygen uptake 
(VO2) at the gas exchange threshold (GET) was used as a submaximal index of exercise capacity 
as it demarcates the boundary between moderate and heavy exercise intensity domains (1). The 
obtainment of the GET was determined as the oxygen uptake (VO2) at which the carbon dioxide 
output (VCO2) increased out of proportion with respect to VO2 and there was an increase in 
ventilation/oxygen uptake (VE/VO2) with no increase in VE/VCO2, as previously described (2). 
Due to the absence of a physician, population age, and potential risk of adverse responses, 






All statistical analyses were performed by using SigmaStat 2.0 (Jandel Scientific, San 
Rafael, CA).  All continuous variables are reported as mean ± SD unless otherwise stated. To 
determine the influence of ADT history (group) and exercise on 2-dimensional and tissue 
Doppler echocardiography variables a two-way repeated-measures ANOVA was performed, 
with significant changes in the within and between groups evaluated via a post hoc Student-





Chapter 3 - Results 
Demographic and clinical parameters for ADT and non-ADT groups are presented in 
Table 1. There were no differences in age, height, mass, and BMI between groups. GET was not 
different between groups. Cancer staging between the ADT and non-ADT groups are as follows: 
(Stage 1-2: ADT n=5, non-ADT n=8); (Stage 3-4: ADT n=4, non-ADT n=1). Three patients in 
the ADT group and seven patients in the non-ADT group had a prostatectomy procedure. Two 
ADT patients were treated via Combined Androgen Blockade which utilizes Leuprolide with 
Bicalutamide (LHRH agonist plus an antiandrogen, respectively) to block multiple pathways of 
testosterone production. Total serum testosterone levels were significantly different between 
groups (Table 1).  
 
2-dimensional and tissue Doppler echocardiography. Heart rate, SBP, DBP, and MAP 
responded similarly between groups in response to exercise (Table 2). Rate Pressure Product 
(RPP) and was used to define myocardial work and was not significantly different between 
groups at rest or exercise. Similarly, pulmonary VO2 was not different between groups during 
exercise. LVEF, EDV, and ESV were not different at rest nor exercise when comparing the ADT 
to non-ADT groups (Figure 1). Stroke volume and cardiac output increased to a similar extent in 
response to exercise with each group. 
 
MVdecT was not different at rest when comparing ADT and non-ADT groups. In the 
ADT group, MVdecT did not change from rest to exercise. However, in the non-ADT group, 
MVdecT was significantly faster during exercise compared to rest, which was also significantly 
faster than the ADT group during exercise (Figure 2). Peak MV E-wave velocity and A-wave 
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velocity increased with exercise in both groups, with no differences between groups. In both 
groups, the E/A ratio significantly changed from rest to exercise and was not different between 
groups.  
 
Tissue Doppler echocardiographic measurements of LV systolic and diastolic function 
are presented in Table 3 and Figure 3. LV longitudinal septal wall systolic strain was not 
different at rest between ADT and non-ADT groups (Figure 3A, p = 0.9). However, in response 
to exercise the non-ADT group observed a significant increase in longitudinal strain from rest (p 
= 0.03) that was not observed in the ADT group (p =0.4). The longitudinal strain during exercise 
was significantly lower in the ADT group compared with non-ADT subjects (p = 0.02). At rest, 
LV septal wall longitudinal strain rate in systole (SRsys) and early filling (SRe) were not 
different between groups (SRsys: p = 0.9; SRe: p = 0.8) (Figure 3).  In the ADT group, SRsys 
did not significantly change from rest to exercise (p = 0.07). However, in the non-ADT group, 
SRsys increased from rest to exercise by 28% (SRsys: p = 0.02). In both groups, SRe 
significantly changed from rest to exercise (ADT p = 0.003; Non-ADT 0.003). However, SRe 
was not significantly different between groups (Rest p = 0.8; Exercise p = 0.8). Sm, Em, and Am 





Chapter 4 - Discussion 
The present investigation evaluated LV function, with noninvasive imaging techniques, at 
rest and submaximal exercise in prostate cancer survivors with a history of ADT and 
demonstrated a variety of abnormalities, particularly with exercise. These include a negatively 
impacted LV systolic strain, systolic strain rate, and MVdecT, in the ADT group in response to 
exercise compared to prostate cancer survivors not treated with ADT. These data confirm our 
hypothesis that prostate cancer patients with a history of ADT have decreased LV systolic and 
diastolic function in response to an increased myocardial work via exercise compared non-ADT 
patients. However, these findings do not support our hypothesis that prostate cancer patients with 
a history of ADT will have decreased LV systolic and diastolic functional parameters compared 
to non-ADT controls at rest. Given the clinical utility of LV strain and strain rate imaging (25), 
particularly during exercise (26), these findings suggest important clinical information is be 
gained during submaximal exercise in prostate cancer survivors with a history of ADT that 
cannot be obtained at rest.  
 
The impact of previous ADT and its association with long-term CVD morbidity and 
mortality risk remain controversial (16). However, the present investigation shows that 
myocardial changes are present in prostate cancer survivors who have underwent ADT (Figure 
3). According to Saigal et al. (2007), ADT-induced hypotestosteronemia increases cardiac 
morbidity by 20% in the first 12 months of treatment (21). Further, Keating et al. (2006) 
indicated an increased risk for myocardial infarction, coronary heart disease, and sudden cardiac 
death with ADT (13). Conversely, Efstathiou et al. (2009) observed a 3% decreased CVD 
mortality in men with a history of ADT (4). Because of this significant controversy from these 
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retrospective epidemiological studies and potential clinical implications, we performed a set of 
experiments to determine if prior ADT in prostate cancer survivors altered subclinical 
measurements of LV function at rest and exercise. As such, the present investigation shows men 
previously treated with ADT for an average treatment duration of 29 months had significantly 
different LV responses to submaximal exercise when compared to a group of match non-ADT 
cancer survivor controls. These present findings lend support to the idea of a potential adverse 
relationship between ADT and long-term cardiovascular health.  
 
Routine clinical parameters of myocardial function such as LVEF have important 
limitations when attempting to evaluate early changes in subclinical myocardial function (10). 
Specifically, changes of  ≥10% in LVEF are required to adequately detect differences and, 
therefore this measure may not be sensitive enough nor completely reflect sub-clinical systolic 
dysfunction (19, 27). Furthermore, LVEF only provides information on systolic dysfunction, 
which is concerning given the increased recognition of LV diastolic dysfunction in several 
clinical populations (20). As such, recent studies have demonstrated the clinical importance of 
myocardial deformation imaging for evaluating regional systolic and diastolic function as 
markers of early myocardial changes to provide valuable insight into the development of 
subsequent CVD onset (27). For example, Thavendiranathan et al. (2014) reviewed the efficacy 
of myocardial strain imaging for the early detection of cardiotoxicity following cancer 
chemotherapy (27). They report that LV strain and strain rate demonstrated a range of 
dysfunctional reductions in myocardial function from 9% to 20% and confirm that these changes 
occur prior to changes in LVEF. Thus, this recent evidence highlights the potential prognostic 
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value of echocardiographic myocardial deformation parameter measures for the evaluation of 
subclinical myocardial dysfunction.   
 
The present study takes important steps in exploring the utility of non-invasive 
myocardial deformation imaging in the evaluation of the long-term cardiac effects associated 
with ADT in prostate cancer survivors. Importantly, we established that decreases in parameters 
of myocardial deformation could occur independent of changes in LVEF in this population. 
Similar to the findings of Thavendiranathan et al. (2014) investigating anthracycline-
chemotherpy induced cardiotoxicity, prostate cancer survivors with a history of ADT experience 
a degree of LV systolic dysfunction, even in the context of a normal LVEF (27). Additionally, as 
described by Lancellotti et al. (2016), exercise as a stressor reveals myocardial mechanical 
abnormalities and dysfunction, that are otherwise obscure at rest (15). We utilized an exercise 
echocardiography protocol from Tan et al. (2009) that clamped each subject to a submaximal HR 
of 100BPM, given that many echocardiography parameters are heart rate dependent (26). 
Additionally, matching heart rate resulted in a similar myocardial oxygen consumption (i.e., 
RPP) between groups, which allowed for comparisons of strain and strain rate to be drawn 
between groups (14). From this exercise protocol, we observed that men with a history of ADT 
demonstrated a lack of change in LV systolic strain and strain rate from rest to exercise, whereas, 
the non-ADT controls observed the typical (26) significant increase in systolic strain and strain 
rate with exercise. This indicates that men who have a history of ADT may be experiencing a 
variety of systolic LV abnormalities that are only manifest in response to mild increases in 
myocardial work (i.e., exercise). This altered strain and strain rate response is therefore 
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suggestive of an impaired contractile performance within the cardiomyocytes often associated 
with systolic dysfunction (25, 31). 
 
In addition to the changes in LV systolic function, the present investigation also 
demonstrated differences in MVdecT between the ADT patients and non-ADT controls, 
indicating some degree of LV diastolic dysfunction. According to Garcia et al. (1998), a delayed 
relaxation (i.e., increased MVdecT) often occurs in patients with stage 1 diastolic dysfunction 
(5). These patients typically have a reduced LV relaxation rate and are usually asymptomatic. In 
the present study, additional markers of diastolic function such as the E/A ratio and strain rate in 
early filling, were not different between groups, suggesting that the association with LV diastolic 
abnormalities in those with ADT history may be minor.  
 
Mechanistically the adverse effects of ADT on myocardial function are well supported in 
animal models. Tsang et al. (2008) utilized isolated animal hearts to determine that 
hypotestosteronemia significantly alters LV diastolic pressures and systolic/diastolic myocardial 
velocities (29). Furthermore, male rodents with induced hypotestosteronemia experience a 34% 
reduction in calcium-myosin adenosine triphosphate-ase (ATP-ase) activity which was used as a 
marker of cardiomyocyte contractile performance, along with reductions in LVEF, peak systolic 
pressure, and myocardial oxygen consumption (22). Similarly, Golden et al. (2004) observed a 
twofold dysfunctional increase in myosin heavy chain-B transcripts and an 80% decrease in 
myosin heavy chain-A transcript levels in the rodent heart following hypotestosteronemia (9). 
These dysfunctional changes were associated with a 16% increase in time to peak shortening, an 
18% increase in relaxation time and an 80% decrease in sodium/calcium pump gene expression 
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(8). These findings, coupled with the controversial clinical CVD outcome data in human prostate 
cancer survivors, highlights how complex and limited our understanding of long-term 
cardiovascular health in prostate cancer survivors is in those treated with ADT.   
 
Implications and Experimental Considerations 
 
With current biomedical technology, measures of regional deformation and contractile 
function are appropriate for the clinical setting and may provide valuable prognostic information 
that can be used to guide various preventative strategies (25). As the present study demonstrates, 
detecting pre-symptomatic cardiac abnormalities can be achieved, particularly with submaximal 
exercise, and appears to be critical for assessing preclinical cardiac abnormalities in patients 
undergoing long-term therapeutic cancer treatments such as ADT. This data suggests that men 
with a history of ADT may have myocardial abnormalities at mild levels of exercise. Evaluating 
these patients may require exercise to determine underlying dysfunction that remains unseen 
while the individual is at rest.  
 
Several experimental limitations should be considered when interpreting the study 
findings. First, the cross-sectional nature of the present study precludes definitive assessment of 
the direct effects of ADT on LV function. However, it does provide some of the first evidence of 
sub-clinical LV systolic dysfunction during exercise in this population. In the present study, all 
patients continued their normal medications throughout their participation in this study, which 
may have impacted the results. According to Wang et al. (2008), the use of antihypertensive 
drugs would be expected to improve symptomatic cardiovascular responses; therefore, given that 
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antihypertensive drugs were primarily taken by the ADT group, the significant difference 
between groups in the current study may have been potentiated had medications been withheld 
(30). There was also a range of times since prostate cancer diagnosis for the patients enrolled in 
the current study, with the ADT group having a range of 6-219 months and the non-ADT group 
had a range of 1-223 months. According to results from Keating et al. (2013) men treated with 
ADT within 252 months (21 years) of diagnosis remain at a greater risk of myocardial infarction 
compared to non-ADT controls (12). Furthermore, regarding the total time receiving ADT for 
the present study, the ADT cohort had a range of 3-84 total months of treatment, which is similar 
to that of Gilbert et al. (2013) who reported decreased in cardiovascular function in men 
receiving ADT with a range of 6-133 total months of treatment (7).  
 
In conclusion, this is the first investigation, to our knowledge, to demonstrate a 
combination of dysfunctional LV systolic and diastolic parameters in the prostate cancer group 
with a history of ADT in response to submaximal exercise. These decreases in LV mechanics 
suggest that a history of ADT may have an adverse effect of cardiac function, which may 
contribute to the increased long-term risk of cardiovascular disease morbidity and mortality 
associated with cancer treatment. However, future work will be required to determine if these 
measures, at rest and during exercise, will be a useful parameter for the prediction of long-term 
CVD development. Furthermore, longitudinal measurements of these parameters may be 













Table 1. Demographic and clinical characteristics 






Age (years) 68 ± 8 65 ± 3 0.16 
Height (cm) 179 ± 9 176 ± 5 0.3 
Mass (kg) 92 ± 8 87 ± 12 0.4 
BMI (kg/m^2) 28.7 ± 4 28 ± 4 0.8 
GET (ml/kg/min) 14.3 ± 2.9 13.9 ± 2.7 0.7 
Months since diagnosis 75 ± 70 85 ± 80 0.8 
Months on ADT 29 ± 32 -  
Leuprolide cumulative dose 
(mg) 
209 ± 223 -  
Bicalutamide (mg) 425 ± 106 -  
Testosterone level (ng/dl) 63 ± 146 407 ±168 0.04 
Radiation 5 2 0.1   





Table 2 - Hemodynamic Variables 
 
  
























        
Heart rate (BPM) 65 ± 12 103 ± 4 <0.001 72 ± 7 103 ± 4 <0.001 0.08r 
       0.9e 
Systolic BP (mmHg) 139 ± 19 184 ± 14 <0.001 142 ± 17 174 ± 25 <0.001 0.8r 
       0.2e 
Diastolic BP (mmHg) 68 ± 10 85 ± 7 <0.001 76 ± 8 89 ± 11 0.001 0.1r 
       0.4e 
MAP (mmHg) 93 ± 13 121 ± 9 <0.001 101 ± 11 120 ± 18 <0.001 0.3r 
       0.9e 
RPP (BPM x mmHg) 9231 ± 2723 18909 ± 1565 <0.001 10291 ± 1888 17838 ± 2590 <0.001 0.4r 
       0.3e 
Pulmonary VO2 (l/min)  1.1 ± 0.2   0.9 ± 0.3   
       0.1e 
mean±SD. r comparison between ADT and non-ADT at rest. e comparison between ADT and non-ADT during exercise. BP, blood pressure; 
MAP, mean arterial pressure; RPP, rate pressure product; VO2, rate of oxygen consumption; 
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Table 3. Echocardiography 






















LVEF (%) 64 ± 0.07 67 ± 0.05 0.08 63 ± 0.05 67 ± 0.06 0.06 0.7r 
       0.8e 
Cardiac output (l/min) 4.5 ± 1.2 7.9 ± 1.7 <0.001 4.7 ± 0.6 7.6 ± 1.4 <0.001 0.8r 
       0.6e 
MV Deceleration Time (ms) 203 ± 62 218 ± 71 0.8 224 ± 65 142 ± 36 0.01 0.6r 
       0.03e 
MV E-wave velocity (cm/s) 61 ± 17 106 ± 13 <0.001 65 ± 18 90 ± 20 <0.001 0.3r 
       0.06e 
MV A-Wave Velocity (cm/s) 67 ± 17 92 ± 20 0.004 68 ± 17 83 ± 27 0.03 0.8r 
       0.6e 
MV E/A Ratio 0.96 ± 0.4 1.19 ± 0.2 <0.001 0.96 ± 0.1  1.12 ± 0.3 0.02 0.7r 
       0.7e 
Sm (cm/s) 7.03 ± 1.8 10.4 ± 2.1 0.02 8.5 ± 2.6 9.03 ± 2.1 0.8 0.2r 
       0.4e 
Em (cm/s) 7.97 ± 1.8 10.6 ± 1.2 0.07 8.2 ± 2.1 11 ± 3.1 0.2 0.6r 
       0.9e 
Am (cm/s) 7.6 ± 1.8 10.2 ± 3.3 0.1 9.6 ± 2.7  10 ± 2.6 0.7 0.1r 
       0.8e 
mean±SD. r comparison between ADT and non-ADT at rest. e comparison between ADT and non-ADT during exercise.  
       LVEF, left ventricular ejection fraction; MV, mitral valve; E-wave, early transmitral flow velocity; A-wave, late transmitral flow velocity; 
Sm, peak systolic myocardial mitral annular velocity by color tissue Doppler imaging; Em, peak early diastolic myocardial mitral annular 
velocity by color tissue Doppler imaging; Am, peak late diastolic myocardial mitral annular velocity by color tissue Doppler imaging; 
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Figure 1 - Left ventricular systolic and diastolic volumes from rest to exercise in the ADT 
and non-ADT groups. Mean and individual LV end diastolic volume (A), end systolic volume 
(B), and stroke volume (C). * denotes significant difference from rest to exercise. 
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Figure 2 - Mitral Valve deceleration time from rest to exercise in the ADT and non-ADT 
groups. Mean and individual mitral valve deceleration time. * denotes significant difference 




Figure 3 - Left ventricular systolic and diastolic function from rest to exercise in the ADT 
and non-ADT groups. Mean and individual LV septal wall systolic strain (A), strain rate in LV 
systole (B), and strain rate in LV early filling diastole (C). * denotes significant difference from 
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